Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

In the last several years, global market of Neuromyelitis Optica Drug developed with the production growth rate about 4%. In 2015 global capacity of Neuromyelitis Optica Drug is more than 9100 K units.

North America is the largest supplier of Neuromyelitis Optica Drug, with a production market share of 59.3% and a consumption market share of 18.7%.

Europe is the second largest supplier of Neuromyelitis Optica Drug, following North America with the production market share of 25% and the consumption market share of 27%. Asia (Ex China) is another important market of Neuromyelitis Optica Drug, enjoying 31.8% sales market share.

According to this study, over the next five years the Neuromyelitis Optica Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Neuromyelitis Optica Drug business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuromyelitis Optica Drug market by product type, application, key manufacturers and key regions and countries.

This study considers the Neuromyelitis Optica Drug value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.

Glucocorticoids

Immunoglobulin

Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.

Acute attack

Remission prophylactic treatment

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Spain

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.

Pfizer

FRESENIUS

TEVA

SANDOZ

Intas

Gyjtrs

NANG KUANG

Tianjin Kingyork

Baxter

CSL

Grifols

Octapharma

CBOP

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

To study and analyze the global Neuromyelitis Optica Drug consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.

To understand the structure of Neuromyelitis Optica Drug market by identifying its various subsegments.

Focuses on the key global Neuromyelitis Optica Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Neuromyelitis Optica Drug with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Neuromyelitis Optica Drug submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Contents

2019-2024 Global Neuromyelitis Optica Drug Consumption Market Report

1 Scope of the Report

1.1 Market Introduction

1.2 Research Objectives

1.3 Years Considered

1.4 Market Research Methodology

1.5 Economic Indicators

1.6 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Neuromyelitis Optica Drug Consumption 2014-2024

2.1.2 Neuromyelitis Optica Drug Consumption CAGR by Region

2.2 Neuromyelitis Optica Drug Segment by Type

2.2.1 Glucocorticoids

2.2.2 Immunoglobulin

2.3 Neuromyelitis Optica Drug Consumption by Type

2.3.1 Global Neuromyelitis Optica Drug Consumption Market Share by Type (2014-2019)

2.3.2 Global Neuromyelitis Optica Drug Revenue and Market Share by Type (2014-2019)

2.3.3 Global Neuromyelitis Optica Drug Sale Price by Type (2014-2019)

2.4 Neuromyelitis Optica Drug Segment by Application

2.4.1 Acute attack

2.4.2 Remission prophylactic treatment

2.5 Neuromyelitis Optica Drug Consumption by Application

2.5.1 Global Neuromyelitis Optica Drug Consumption Market Share by Application (2014-2019)

2.5.2 Global Neuromyelitis Optica Drug Value and Market Share by Application (2014-2019)

2.5.3 Global Neuromyelitis Optica Drug Sale Price by Application (2014-2019)

3 Global Neuromyelitis Optica Drug by Players

3.1 Global Neuromyelitis Optica Drug Sales Market Share by Players

3.1.1 Global Neuromyelitis Optica Drug Sales by Players (2017-2019)

3.1.2 Global Neuromyelitis Optica Drug Sales Market Share by Players (2017-2019)

3.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players

3.2.1 Global Neuromyelitis Optica Drug Revenue by Players (2017-2019)

3.2.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2017-2019)

3.3 Global Neuromyelitis Optica Drug Sale Price by Players

3.4 Global Neuromyelitis Optica Drug Manufacturing Base Distribution, Sales Area, Product Types by Players

3.4.1 Global Neuromyelitis Optica Drug Manufacturing Base Distribution and Sales Area by Players

3.4.2 Players Neuromyelitis Optica Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 Neuromyelitis Optica Drug by Regions

4.1 Neuromyelitis Optica Drug by Regions

4.1.1 Global Neuromyelitis Optica Drug Consumption by Regions

4.1.2 Global Neuromyelitis Optica Drug Value by Regions

4.2 Americas Neuromyelitis Optica Drug Consumption Growth

4.3 APAC Neuromyelitis Optica Drug Consumption Growth

4.4 Europe Neuromyelitis Optica Drug Consumption Growth

4.5 Middle East & Africa Neuromyelitis Optica Drug Consumption Growth

5 Americas

5.1 Americas Neuromyelitis Optica Drug Consumption by Countries

5.1.1 Americas Neuromyelitis Optica Drug Consumption by Countries (2014-2019)

5.1.2 Americas Neuromyelitis Optica Drug Value by Countries (2014-2019)

5.2 Americas Neuromyelitis Optica Drug Consumption by Type

5.3 Americas Neuromyelitis Optica Drug Consumption by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Neuromyelitis Optica Drug Consumption by Countries

6.1.1 APAC Neuromyelitis Optica Drug Consumption by Countries (2014-2019)

6.1.2 APAC Neuromyelitis Optica Drug Value by Countries (2014-2019)

6.2 APAC Neuromyelitis Optica Drug Consumption by Type

6.3 APAC Neuromyelitis Optica Drug Consumption by Application

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 Key Economic Indicators of Few APAC Countries

7 Europe

7.1 Europe Neuromyelitis Optica Drug by Countries

7.1.1 Europe Neuromyelitis Optica Drug Consumption by Countries (2014-2019)

7.1.2 Europe Neuromyelitis Optica Drug Value by Countries (2014-2019)

7.2 Europe Neuromyelitis Optica Drug Consumption by Type

7.3 Europe Neuromyelitis Optica Drug Consumption by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

7.9 Spain

7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

8.1 Middle East & Africa Neuromyelitis Optica Drug by Countries

8.1.1 Middle East & Africa Neuromyelitis Optica Drug Consumption by Countries (2014-2019)

8.1.2 Middle East & Africa Neuromyelitis Optica Drug Value by Countries (2014-2019)

8.2 Middle East & Africa Neuromyelitis Optica Drug Consumption by Type

8.3 Middle East & Africa Neuromyelitis Optica Drug Consumption by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact

9.1.1 Growing Demand from Key Regions

9.1.2 Growing Demand from Key Applications and Potential Industries

9.2 Market Challenges and Impact

9.3 Market Trends

10 Marketing, Distributors and Customer

10.1 Sales Channel

10.1.1 Direct Channels

10.1.2 Indirect Channels

10.2 Neuromyelitis Optica Drug Distributors

10.3 Neuromyelitis Optica Drug Customer

11 Global Neuromyelitis Optica Drug Market Forecast

11.1 Global Neuromyelitis Optica Drug Consumption Forecast (2019-2024)

11.2 Global Neuromyelitis Optica Drug Forecast by Regions

11.2.1 Global Neuromyelitis Optica Drug Forecast by Regions (2019-2024)

11.2.2 Global Neuromyelitis Optica Drug Value Forecast by Regions (2019-2024)

11.2.3 Americas Consumption Forecast

11.2.4 APAC Consumption Forecast

11.2.5 Europe Consumption Forecast

11.2.6 Middle East & Africa Consumption Forecast

11.3 Americas Forecast by Countries

11.3.1 United States Market Forecast

11.3.2 Canada Market Forecast

11.3.3 Mexico Market Forecast

11.3.4 Brazil Market Forecast

11.4 APAC Forecast by Countries

11.4.1 China Market Forecast

11.4.2 Japan Market Forecast

11.4.3 Korea Market Forecast

11.4.4 Southeast Asia Market Forecast

11.4.5 India Market Forecast

11.4.6 Australia Market Forecast

11.5 Europe Forecast by Countries

11.5.1 Germany Market Forecast

11.5.2 France Market Forecast

11.5.3 UK Market Forecast

11.5.4 Italy Market Forecast

11.5.5 Russia Market Forecast

11.5.6 Spain Market Forecast

11.6 Middle East & Africa Forecast by Countries

11.6.1 Egypt Market Forecast

11.6.2 South Africa Market Forecast

11.6.3 Israel Market Forecast

11.6.4 Turkey Market Forecast

11.6.5 GCC Countries Market Forecast

11.7 Global Neuromyelitis Optica Drug Forecast by Type

11.8 Global Neuromyelitis Optica Drug Forecast by Application

12 Key Players Analysis

12.1 Pfizer

12.1.1 Company Details

12.1.2 Neuromyelitis Optica Drug Product Offered

12.1.3 Pfizer Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2017-2019)

12.1.4 Main Business Overview

12.1.5 Pfizer News

12.2 FRESENIUS

12.2.1 Company Details

12.2.2 Neuromyelitis Optica Drug Product Offered

12.2.3 FRESENIUS Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2017-2019)

12.2.4 Main Business Overview

12.2.5 FRESENIUS News

12.3 TEVA

12.3.1 Company Details

12.3.2 Neuromyelitis Optica Drug Product Offered

12.3.3 TEVA Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2017-2019)

12.3.4 Main Business Overview

12.3.5 TEVA News

12.4 SANDOZ

12.4.1 Company Details

12.4.2 Neuromyelitis Optica Drug Product Offered

12.4.3 SANDOZ Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2017-2019)

12.4.4 Main Business Overview

12.4.5 SANDOZ News

12.5 Intas

12.5.1 Company Details

12.5.2 Neuromyelitis Optica Drug Product Offered

12.5.3 Intas Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2017-2019)

12.5.4 Main Business Overview

12.5.5 Intas News

12.6 Gyjtrs

12.6.1 Company Details

12.6.2 Neuromyelitis Optica Drug Product Offered

12.6.3 Gyjtrs Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2017-2019)

12.6.4 Main Business Overview

12.6.5 Gyjtrs News

12.7 NANG KUANG

12.7.1 Company Details

12.7.2 Neuromyelitis Optica Drug Product Offered

12.7.3 NANG KUANG Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2017-2019)

12.7.4 Main Business Overview

12.7.5 NANG KUANG News

12.8 Tianjin Kingyork

12.8.1 Company Details

12.8.2 Neuromyelitis Optica Drug Product Offered

12.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2017-2019)

12.8.4 Main Business Overview

12.8.5 Tianjin Kingyork News

12.9 Baxter

12.9.1 Company Details

12.9.2 Neuromyelitis Optica Drug Product Offered

12.9.3 Baxter Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2017-2019)

12.9.4 Main Business Overview

12.9.5 Baxter News

12.10 CSL

12.10.1 Company Details

12.10.2 Neuromyelitis Optica Drug Product Offered

12.10.3 CSL Neuromyelitis Optica Drug Sales, Revenue, Price and Gross Margin (2017-2019)

12.10.4 Main Business Overview

12.10.5 CSL News

12.11 Grifols

12.12 Octapharma

12.13 CBOP

13 Research Findings and Conclusion

List of Tables and Figures

Figure Picture of Neuromyelitis Optica Drug

Table Product Specifications of Neuromyelitis Optica Drug

Figure Neuromyelitis Optica Drug Report Years Considered